BioNxt Solutions Inc · CSE:BNXT
BioNxt Solutions — XPhyto Therapeutics — Investor Presentation (June 2021)
16 slides from BioNxt Solutions's investor presentation, June 2021
Slide 1: A next generation bioscience company
June 2021 A next generation bioscience company Corporate Presentation
Slide 2: Agenda
Agenda 01 Company Overview 02 Diagnostics 03 Therapeutics 04 Appendix
Slide 3: Company Overview
Company Overview 01
Slide 4: Company Profile
Company Profile Diagnostics Lead product is a rapid point-of-care COVID-19 RT-PCR diagnostic test launched in Europe in April 2021. Diagnostic development pipeline includes a portfolio of real-time ultra low-cost infectious disease biosensors. Drug Delivery Bioscience Company Platform technology to
Slide 5: Buy and Build Strategy
Buy and Build Strategy XPhyto’s buy and build University of Alberta & strategy is creating a 02. Leading German University Two psychedelic medicine collaborations portfolio of late-stage 2021 Collaborations underway with leading institutions in Germany and Canada therapeutic and diagnostic products
Slide 6: Pipeline
Pipeline Diagnostics Indication Design and Feasibility Final CE-Mark Market development study validation Rapid RT-PCR COVID-19 Q2 2021 Ultra-rapid LFA COVID-19 Q3 2021 Peptide biosensor – ODF Infectious disease (multiple) Q4 2021 Peptide biosensor – ODF Oral health (multiple) Q4 2021 Therapeutics In
Slide 7: Diagnostics
Diagnostics 02
Slide 8: COVID-19 RT-PCR Diagnostic Test
COVID-19 RT-PCR Diagnostic Test Commercial Launch April 2021 Rapid test in 25 minutes 5 min hands-on time and 20 mins reaction only Point-of-care diagnostic device for use with minimal lab equipment Low detection limit diagnostic reliability of PCR tests Cost-effectiveness enables broad testing Easi
Slide 9: Diagnostic Pipeline
Diagnostic Pipeline Diagnostics Indication Design and Feasibility Final CE-Mark Market development study validation Rapid RT-PCR COVID-19 Q2 2021 Ultra-rapid LFA COVID-19 Q3 2021 Peptide biosensor – ODF Infectious disease (multiple) Q4 2021 Peptide biosensor – ODF Oral health (multiple) Q4 2021 Comp
Slide 10: Therapeutics
Therapeutics 03
Slide 11: Therapeutic Pipeline
Therapeutic Pipeline Therapeutics Indication Formulation and Preclinical Clinical study Market development study Pilot Pivotal Rotigotine – TDS Parkinson’s Disease Q1 2021 Cannabidiol Epilepsy, other Q2 2021 (CBD) – ODF Tetrahydrocannabinol Nausea / Anorexia, other Q3 2021 (THC) – ODF CBD:THC combin
Slide 12: Recent Developments Outlook
Recent Developments Outlook Business Highlights Diagnostic Pipeline Exclusive development partnership with 3a-Diagnostics GmbH COVID-19 PCR Test launched Q2, 2021 Acquisition of Vektor Pharma TF GmbH Oral biosensors launch Q4, 2021 Exclusive psychedelic API production partnerships Therapeutic Pipeli
Slide 13: Investment Highlights
Investment Highlights World-class drug delivery expertise Efficient M&A execution A pipeline of novel thin-film drug Management committed to building delivery formulations, offering precise, shareholder value through efficient, optimized bioavailability buy & build strategy Disruptive R&D collaborat
Slide 14: Market Overview
Market Overview Thin film products Rapid-diagnostic test COVID-19 test Global thin film drugs market is The global rapid test market is projected The global COVID-19 diagnostics expected to grow to USD $29.2 billion to reach USD $39.1 billion by 2023 with market size is estimated at by 2024 at a CAG
Slide 15: Management and team
Management and team Hugh Christopher Prof. Dr. Raimar Wolfgang Prof. Dr. Thomas Prof. Dr. Wolfgang Manfred Rogers Ross Löbenberg Probst Beckert Eisenreich Buchberger LLB CEO & director CPA, CFO Director Director & Managing director Executive advisor Head of Corp. managing director Development Lawyer
Slide 16: Contact
Contact XPhyto CEO Hugh Rogers hrogers@xphyto.com +1 604 250 6162 IR Canada & US Bioscience company Knox Henderson with proven therapeutics khenderson@xphyto.com and innovative diagnostics +1 604 551 2360 approaching the market. Made in Germany EUROPE IR & PR MC Services AG xphyto@mc-services.eu +49
XPhyto Therapeutics — Investor Presentation (June 2021) on 6ix